Chronic Lymphocytic Leukemia with t(14;18)(q32;q21) As a Sole Cytogenetic Abnormality

Ghaleb Elyamany1,2, Kamal Fadalla3, Hatem Elghezal1, Omar Alsuhaibani1, Hani Osman3 and Abdulaziz Al-Abulaaly3

1Department of Central Military Laboratory and Blood Bank, Prince Sultan Military Medical City, Riyadh, Saudi Arabia. 2Department of Hematology and Blood Bank, Theodor Bilharz Research Institute, Giza, Egypt. 3Department of Adult Clinical Hematology and Stem cell Therapy, Prince Sultan Military Medical City, Riyadh, Kingdom of Saudi Arabia.

ABSTRACT

BACKGROUND: Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. The chromosomal abnormality t(14;18)(q32;q21) is most commonly associated with neoplasms of a follicular center cell origin. However, t(14;18) has also been reported in rare cases of CLL.

OBJECTIVE: We describe the clinicopathologic, immunophenotypic, conventional, and molecular cytogenetic features of two rare cases proven to be CLL morphologically and immunologically in which t(14;18) was found as the sole cytogenetic abnormality.

METHODS: Morphologic, flow cytometric analysis and molecular cytogenetic of peripheral blood and/or bone marrow samples were analyzed.

RESULTS: Cytomorphologically, the cells were small mature lymphocytes without any findings that had characteristics of follicular lymphoma (FL) such as indented or clefted nuclei. Immunologic findings were characteristic of typical CLL without expression of CD10. A cytogenetic study revealed the two cases of CLL carrying t(14;18)(q32;q21).

CONCLUSION: We concluded that CLL with t(14;18) is rare and should be differentiated from FL as the therapy is highly diverse between both diseases. Using immunoglobulin heavy chain gene (IGH) probes are important in the workup of patients with suspected CLL and suggest that the IGH probe should be used routinely in all CLL fluorescence in situ hybridization (FISH) panels.

KEYWORDS: chronic lymphocytic leukemia, FISH, t(14;18)

CITATION: Elyamany et al. Chronic Lymphocytic Leukemia with t(14;18)(q32;q21) As a Sole Cytogenetic Abnormality. Clinical Medicine Insights: Pathology 2014:7 21–27
doi: 10.4137/CPath.S1781
RECEIVED: June 17, 2014. RESUBMITTED: July 20, 2014. ACCEPTED FOR PUBLICATION: July 20, 2014.

ACADEMIC EDITOR: Dama Laxminarayana, Editor in Chief

TYPE: Original Research

FUNDING: Authors disclose no funding sources.

COMPETING INTERESTS: Authors disclose no potential conflicts of interest.

COPYRIGHT: © the authors, publisher and licensee Libertas Academica Limited. This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License.

CORRESPONDENCE: ghalebelyamany@yahoo.com

This paper was subject to independent, expert peer review by a minimum of two blind peer reviewers. All editorial decisions were made by the independent academic editor. All authors have provided signed confirmation of their compliance with ethical and legal obligations including (but not limited to) use of any copyrighted material, compliance with ICMJE authorship and competing interests disclosure guidelines and, where applicable, compliance with legal and ethical guidelines on human and animal research participants.
extremely rare. In FL, breakpoints of t(14;18) occur in the major breakpoint region (mbt) or in the minor cluster region (mcr) at the 3’ end of BCL2, whereas in CLL the breakpoints have been found to be at the 5’ end juxtaposing BCL2 to the immunoglobulin light chains. However, large series showed BCL2 rearrangements to be rare events in CLL.⁴

Chromosomal translocations are uncommon in CLL, identified in less than 5% of all cases.⁷–¹⁰ t(14;18) is highly unusual in CLL and is found in 1–2% of cases.¹¹–¹⁴

Here we describe two rare cases of CLL carrying t(14;18) (q32;q21). The cells were small mature lymphocytes without any morphologic or immunologic findings that had characteristics of FL, such as cleaved nuclei or CD10 expression.

Materials and Methods

Case selection. We searched the database of the Cytogenetics Laboratory for cases with t(14;18)(q32;q21), other reciprocal chromosomal translocations such as (t14;19)(q32;q13), or variant translocations (t12;19)(q13;p13) and (t19;22)(q13;p11) during the period between January 2010 and June 2014. Out of 96 cases, we identified 2 cases with t(14;18)(q32;q21). Both cases were diagnosed as CLL/small lymphocytic lymphoma (SLL) based on morphologic and immunophenotypic criteria, but no cases with t(14;19)(q32;q13) or the variant translocations were identified. We retrieved clinicopathological data, immunophenotype, and cytogenetics from the medical records. This study was approved by the Ethics and Research Committee of the Department.

Morphologic examination. In each case, we reviewed the peripheral blood (PB) smears, bone marrow (BM) aspirate smears, touch imprints, and core biopsy specimens with more attention given to lymphocyte morphology with respect to atypical features, including indented or cleaved nuclei, the presence of prolymphocytes, immature-large cells, or plasma-cytoid features.

Immunophenotyping. The PB and/or BM samples were subjected to immunophenotypic studies by a flow cytometry using a CD45/side scatter gating strategy to analyze the lymphocyte population. Immunohistochemical stains were performed using routinely fixed, paraffin-embedded tissue sections of BM biopsy and lymph node.

Cytogenetic analysis. Conventional cytogenetic analysis was performed on metaphase cells prepared from PB and/or BM specimens cultured for 24 and 72 hours without mitogens, using standard techniques. A total of 20 metaphases were analyzed, and the result was reported according to International System for Human Cytogenetic Nomenclature (ISCN) 2009.

Fluorescence in situ hybridization (FISH) analysis for common abnormalities associated with CLL was performed using the following probes panel: TP53/CEP17, D13S319/13q34, IGH/CCND1 (DC, DF), IGH/BCL2 (DC, DF), and CEP12 to detect the common cytogenetic abnormalities according to the manufacturer’s instructions (Abbott Molecular, Abbott Park, IL). A total of 200 nuclei were analyzed for every probe test, and the result was reported according to ISCN 2009.

Result

Patients. Table 1 summarizes the laboratory findings and clinical characteristics of the patients at diagnosis.

Case 1: A man in his 70s was known to have hypertensive, ischemic heart disease with a history of recurrent cerebral strokes. In June 2010, he discovered incidentally from the workup of his follow up for previous diseases to have leukocytosis and absolute lymphocytosis. Complete blood count (CBC) at that time showed a hemoglobin (Hb) count of 13.5 g/dL (reference interval, 12.5–18 g/dL), a white blood count of 18.2 × 10⁹/L (reference interval, 4–11 × 10⁹/L), and a platelet count of 188 × 10⁹/L (reference interval, 150–450 × 10⁹/L). Differential count showed 74.2% lymphocytes with the presence of smear cells. The patient was referred to Hematology Clinic because of PB findings that gave initial clinical impression of CLL, which was confirmed by a flow cytometry analysis.

The patient was asymptomatic (no fever, weight loss, or sweating) and clinically stable. Clinical examination was irrelevant. No lymph nodes were palpable and no hepatosplenomegaly was observed. The lactate dehydrogenase (LD) value was within the normal range –215 U/L (reference interval, 135–255 U/L), and the β₂-microglobulin level was elevated –3.5 mg/L (reference interval, 1.09–2.53 mg/L).

Until now, no treatment was given. His WBC count remained stable during follow up. The last follow up was at

| Table 1. Laboratory findings and clinical characteristics of the patients at diagnosis. |
|-----------------|-----------------|-----------------|
| **PARAMETER**   | **CASE 1**      | **CASE 2**      | **REFERENCE INTERVAL** |
| Laboratory findings | 18.2 | 38.4 | 4–11 |
| Lymphocytes (%)  | 74.2 | 78  | 20–40 |
| Hemoglobin (g/l) | 13.5 | 10.8 | 12.5–18 |
| Platelet count (10⁹/l) | 188 | 98  | 150–450 |
| Lactate dehydrogenase (U/l) | 215 | 270 | 135–255 |
| β₂-microglobulin (mg/L) | 3.5 | 5.2 | 1.09–2.53 |

Clinical characteristics

| **AGE/SEX** | **B-SYMPTOMS** | **LYMPHADENOPATHY** | **HEPATOSPLENOMEGALY** | **DISEASE PROGRESSION** | **TREATMENT** | **FOLLOW UP** | **ALIVE/DEAD** |
|-----------|---------------|---------------------|-----------------------|------------------------|--------------|--------------|---------------|
| 70s/male  | No            | No                  | No                    | No                     | No           | Stable       | Alive         | Alive        |
| 50s/male  | No            | Yes                 | No                    | No                     | Yes          | Relapse      | Alive         | Alive        |

Follow up Stable Relapse –
Alive Dead –
April 2014. The patient remained clinically stable, and his WBC count was $24.2 \times 10^9/L$ with 78% lymphocytes, Hb count was 14.2 g/dL, and platelet count was $179 \times 10^9/L$, with no need for treatment. The patient refused to do BM examination during diagnosis and for follow up.

**Case 2:** A man in his 50s was known to be hypertensive and diabetic. In January 2011, he presented with 3 months history of mild enlargement of lymph nodes in the neck and submandibular and inguinal areas, but no B-symptoms or other relevant complaints. His CBC at presentation revealed leukocytosis and absolute lymphocytosis, with an Hb count of 10.8 g/dL, a white blood count of $38.4 \times 10^9/L$, and a platelet count of $98 \times 10^9/L$. Differential count showed that 78% were small, mature-lymphocytosis with the presence of smear cells. Findings gave clinical suspicion of CLL, which was confirmed by a flow cytometry analysis of PB. The LD value (270 U/L) and also the $\beta_2$-microglobulin level (5.2 mg/L) were elevated.

His BM examination also confirms the diagnosis of CLL, and he had disease progression. He was treated by FCR (fludarabine, cyclophosphamide, and rituximab) chemotherapy regimen every 28 days for four cycles. After the treatment, the patient got remission until December 2013 when he presented again with generalized lymphadenopathy mainly cervical and axillary lymphadenopathy and mild leukocytosis. He also had on and off fever with night sweat. At admission, WBC count was $13.8 \times 10^9/L$, Hb count was 11.3 g/dL, and platelet count was $81 \times 10^9/L$. Differential peripheral blood film showed lymphocytosis (60%). Serum $\beta-2$ microglobulin level (10.9 mg/L) and also LD value (277 U/L) were elevated. A computed tomography of the chest, abdomen, and pelvis was done, which showed development of extensive huge mediastinal, axillary, paraaortic, mesenteric, iliac, and inguinal lymphadenopathy with hepatosplenomegaly indicating progression of the disease. BM examination and lymph node biopsy (tru-cut biopsy from the axillary lymph node) were done and reported as relapsed CLL/SLL with no evidence of transformation to high-grade lymphoma. After that, the patient started the same FCR chemotherapy. Currently, the patient is in remission, and his CBC at last follow up at May 2014 revealed an Hb count of 11.6 g/dL, a WBC count of $4.5 \times 10^9/L$, and a platelet count of $109 \times 10^9/L$.

**Morphologic findings.** Lymphocyte morphologic features were considered typical for CLL in both cases. Lymphocytes were mature, small with round nuclei, clumped chromatin, scant cytoplasm, and regular cellular outline. Rare prolymphocytes and broken cells (smudge or smear cells) were seen (Fig. 1). BM examination (case 2) showed lymphoid cells’ infiltration in a nodular pattern. The infiltrates were composed of predominantly small, mature-looking cells with occasionally admixed larger cells. No proliferation centers were identified in the BM (Fig. 2). Lymph node biopsy at relapse showed diffuse effacement of the architecture with small, round lymphocytes with condensed chromatin and scanty cytoplasm (Fig. 3).

**Immunophenotyping findings.** In both cases, FCM analysis showed typical immunophenotyping for CLL and revealed clonal B cells with kappa light chain expression and immunophenotype characteristics of CLL with positivity for CD19, CD20 (weak), CD23, CD22, HLA-DR, and CD5 and negativity for terminal deoxynucleotidyl transferase (TdT), CD10, FMC7, CD38, and myeloid and T-cell markers (Fig. 4).

**Immunohistochemical stains performed on BM biopsy and lymph node specimens (case 2) showed that the lymphoid cells were positive for BCL2, CD20, and CD5. Staining for Ki-67 revealed a low fraction of proliferating cells (<10%). The neoplastic cells were negative for cyclin D1, CD10, and CD3 (Fig. 5A and B).

**Cytogenetic findings.** In case 1, karyotype analysis detected the presence of the balanced reciprocal translocation...
t(14;18)(q32;q21), as a sole chromosomal abnormality in 6 among the 20 analyzed cells. FISH confirms the presence of IGH–BCL2 fusion in 65% of analyzed nuclei. The result of cytogenetic investigations is as follows: 46, XY, t(14;18)(q32;q21)[6]/46, XY[nuc ish (TP53x2)[200]/(D13S319x2)[200]/(CCND1, IGH)x2[200]/(IGHX3), (BCL2x3),(IGH con BCL2x2)[140/200]/(D12Z3)X2[200]. Karyotype analysis was not performed due to an insufficient number of metaphases.

Figure 3. Low power image (H and E) of tru-cut lymph node biopsy of case 2 showing diffuse effacement of the architecture with small, round lymphocytes with condensed chromatin and scanty cytoplasm.

Similarly, in case 2, FISH detected the presence of IGH–BCL2 fusion in 70% of analyzed nuclei and reported as follows: nuc ish (TP53x2)[200]/(D13S319x2)[200]/(CCND1, IGH)x2[200]/(IGHX3), (BCL2x3),(IGH con BCL2x2)[140/200]/(D12Z3)X2[200].

Discussion

CLL is the most common leukemia in adults. The morphologic features and immunophenotype of CLL cells are well characterized. Chromosomal translocations are uncommon in CLL.

t(14;18)(q32;q21) is considered highly specific for FL but has been found also in DLBCL. The presence of t(14;18) is highly unusual in CLL. In the literature, few cases have been reported. Its prevalence is found in 1–2% of cases.

Both patients were men, one in his 70s and one in his 50s at the time of diagnosis. Both patients presented with leukemia, and case 2 also presented with nodal disease at relapse. In our study, although BCL2 gene rearrangement occurs much more frequently in FL, our cases were diagnosed as CLL rather than FL as the lymphocytes had the typical morphologic and immunophenotypic characters of CLL. Lymphocytosis was incidentally discovered without any clinical symptoms in case 1 and with only mild lymphadenopathy without

Figure 4. Flow cytometric analysis of PB sample of case 1 revealed clonal B cells with kappa light chain expression. B cells express CD5, CD19, CD20 (weak) and CD23. FMC-7 and CD10 are negative.
B-symptoms in case 2. Similar to our patients and depending on combination of immunophenotype and morphological studies, few cases of CLL had been reported previously.\textsuperscript{17,18} Also, in our study t(14;18) was the sole karyotypic abnormality, which is extremely rare and has been reported previously in few cases of CLL.\textsuperscript{7,10,11,13,14,17,19}

In the large study by Sen et al that contained 2215 cases of CLL, only 2 cases were identified carrying t(14;18). But unlike our cases, in both patients, in addition to t(14;18), trisomy 12 (+12) was identified in the same clone.\textsuperscript{11}

In the most recently published article by Tang et al who searched for cases of CLL with t(14;18) between 1996 and 2010 and identified 12 cases (less than 1% of all cases) classified as CLL/SLL, only two cases carried t(14;18) as the sole karyotypic abnormality.\textsuperscript{20} This finding with other reported studies,\textsuperscript{7,10,11,13,14,17,19} in addition to the current study, indicates that the overall CLL cases carry t(14;18) (q32;q21) as the sole cytogenetic abnormality is extremely very rare.

In addition to t(14;18), other translocations involving the \textit{BCL2} gene have been shown in rare cases of CLL.\textsuperscript{10,21–23} Dyer et al.\textsuperscript{18} estimated the overall incidence for translocations involving the \textit{BCL2} gene in CLL as 2.3%, with t(14;18) being the most common.

The prognostic significance of t(14;18) in CLL is still a controversial matter.\textsuperscript{17} Some studies have suggested that CLL with molecular and/or cytogenetic evidence of \textit{BCL2} translocations does not appear to be associated with poor prognosis or progressive disease.\textsuperscript{7,8,10,19,24} However, other studies failed to demonstrate a strong association between t(14;18) and an inferior outcome.\textsuperscript{11,13,14,19} Our patient (case 1) is clinically stable, did not need treatment until now (more than 3.5 years), shows no evidence of progression, and had an indolent course while case 2 showed progressive disease and required chemotherapy. After more than 2 years of remission, relapse occurred and the patient presented with extensive generalized lymphadenopathy but without evidence of transformation to high-grade lymphoma. However, as the number of cases of CLL with t(14;18) in all reported studies is very small, prospective studies will be required to assess the prognostic relevance of t(14;18) in CLL.

Some reported studies suggested that the bcl2 translocations occurring in CLL are different from those that typically occur in FL,\textsuperscript{4,18,25} and further molecular analysis studies are needed to confirm this finding as this distinction cannot be made by either conventional cytogenetical methods or by our FISH assay for \textit{IGH} and \textit{BCL2}.\textsuperscript{4,17}

In both patients, the immunophenotypic analysis showed negativity to CD38 although the clinical course in both patients was different as case 1 was clinically stable whereas case 2 showed disease progression. This observation did not support the findings reported by Damle et al who demonstrated that the CD38 expression level was a significant prognostic marker in CLL. CLL with a higher percentage of CD38+ cells (using the 30% cut-off for CD38 positivity) comprised unmutated CLL cases, whereas CLL with lower percentage contained almost the mutated cases indicating CD38 expression in CLL can serve as a surrogate marker for the immunoglobulin variable heavy-chain (\textit{VH}) genes mutation status.\textsuperscript{26–28} Subsequently, CLL can be segregated into two subgroups on the basis of the presence or absence of significant numbers of \textit{VH} gene mutations.\textsuperscript{7,8} However, this finding is currently controversial.\textsuperscript{29–32}
The cellular origin of CLL is still in debate. Extensive molecular investigations of the B-cell receptor (BCR) indicate that 60–65% of CLL patients carry mutated immunoglobulin heavy-chain variable genes, while approximately 35% harbor unmutated IgV genes.26,33

The association with IGHV gene mutations suggests that a fraction of cases derived from germinal center (GC)-experienced B-cells, while the remaining cases (unmutated IGHV genes) derived from B-cells that have undergone differentiation in a GC-independent fashion.34–36 Also, transcriptome analyses of CLL revealed that immunoglobulin variable region (IgV) gene unmutated CLL derived from unmatured mature CD5(+) B cells and mutated CLL derived from a distinct CD5(+)CD27(+) post-germinal center B-cell subset.37,38

Our experience in evaluation of CLL cases included a probe to detect BCL2 gene rearrangement, and if positive, we included both t(14;18) and t(11;14) in a FISH panel to exclude a rare type of negative FL (CD10) and mantle cell lymphoma (MCL), respectively, especially with atypical morphology or immunophenotype as in rare cases overlapping and confusion in diagnosis may occur. Correlation of FISH analysis with clinical, immunophenotypic, and morphological findings is recommended for all cases of CLL, and also lymph node biopsy should exclude diagnosis of FL in cases of CLL with t(14;18) if associated with lymphadenopathy, atypical immunophenotype, and/or atypical morphology.

Summary
We concluded that CLL with t(14;18) is rare and should be differentiated from FL if associated with lymphadenopathy, atypical immunophenotype, and/or atypical morphology as the therapy is highly diverse between both diseases. Also, we conclude that using IGH probes is important in the workup of patients with suspected CLL and suggest that the IGH probe should be used routinely in all CLL FISH panels.

Acknowledgment
The authors would like to acknowledge Mr. Waleed Al-Bissi from Histopathology Division for assistance in this study. Also, they thank Dr. Inesse Ben-Abdallah Bouhajar for her help in the study and collection of cytogenetic data.

Author Contributions
Conceived and designed the experiments: GE, AA. Analyzed the data: GE, HE. Wrote the first draft of manuscript: GE. Contributed to the writing of the manuscript results and conclusions: KF, OA, HO, HE. Jointly developed the structure and arguments for the paper: GE, KF, OA, HO, HE. Made critical revisions and approved final version: GE, AA. All authors reviewed and approved the final manuscript.

REFERENCES
1. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: LARC Press; 2008.
2. Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunophenomenal profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia. 1994;8:3640–5.
3. Feneou EJ, Matutes E, A’Hern RP, et al. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Am J Clin Pathol. 1997;108(4):378–82.
4. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910–6.
5. Jülliusson G, Ocier DG, Fitchett M, et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med. 1990;323:720–4.
6. Yunis JJ, Oken MM, Kaplan ME, Ensrud KM, Howe RR, Theologides A. Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin’s lymphoma. N Engl J Med. 1982;307:1231–6.
7. Lu G, Kong Y, Yue C. Genetic and immunophenotypic profile of IGH@ rearrangement detected by fluorescence in situ hybridization in 149 cases of B-cell chronic lymphocytic leukemia. Cancer Genet Cytofegen. 2010;196:56–63.
8. Mayr C, Speicher MR, Kofer DM, et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood. 2006;107:742–51.
9. Huh YO, Schweighofler CD, Ketterling RP, et al. Chronic lymphocytic leukemia with t(14;19)(q32;q13) is characterized by atypical morphologic and immunophenotypic features and distinctive genetic features. Am J Clin Pathol. 2013;139:866–96.
10. Cavazzini F, Hernandez JA, Gozzetti A, et al. Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukemia identify a disease subset with poor prognosis. Br J Haematol. 2008;142:529–37.
11. Sen F, Lai R, Albitar M. Chronic lymphocytic leukemia with t(14;18) and trisomy 12. Arch Pathol Lab Med. 2002;126:1543–6.
12. Haferlach C, Dicker F, Schnittert S, Kern W, Haferlach T. Comprehensive genetic characterization of CLL: a study on 306 cases analyzed with chromosome banding analysis, interphase FISH, IGH(14) status and immunophenotyping. Leukemia. 2007;21:2442–51.
13. Pet N, Meeus P, Chatelain B, et al. Translocation t(14;18) is not associated with inferior outcome in chronic lymphocytic leukemia. Leukemia. 2009;23:1201–4.
14. Baggio L, Geay MO, Gazzo S, et al. In non-follicular lymphoproliferative disorders, IGH/BCL2-fusion is not restricted to chronic lymphocytic leukemia. Br J Haematol. 2012;158:489–98.
15. Nelson BP, Gupta R, Dewald GW, Paternoster SF, Rosen ST, Peterson LC. Chronic lymphocytic leukemia FISH panel: impact on diagnosis. Am J Clin Pathol. 2007;128(1):321–2.
16. Rowley JD. Chromosome studies in the non-Hodgkin lymphomas: the role of the 14:18 translocation. J Clin Oncol. 1988;6:919–25.
17. Nowakowski GS, Dewald GW, Hoyer JD, et al. Interphase fluorescence in situ hybridization with an IGH probe is important in the evaluation of patients with a clinical diagnosis of chronic lymphocytic leukemia. Br J Haematol. 2005;130(1):36–42.
18. Dyer MJ, Zani VJ, Lu WZ, et al. BCL2 translocations in leukemias of mature B cells. Blood. 1994;83:3682–8.
19. Kojima K, Taniwaki M, Yoshino T, et al. Trisomy 12 and t(14;18) in B-cell chronic lymphocytic leukemia. Int J Hematol. 1998;67:199–203.
20. Tang G, Banks HE, Sargent RL, Medeiros LJ, Abruzzo LV. Chronic lymphocytic leukemia with t(14;18)(q32;q21). Hum Pathol. 2013;44(4):598–605.
21. Cavazzini F, Rizzotto L, Soffritti O, et al. Clonal evolution including 14q32/IGH translocations in chronic lymphocytic leukemia: analysis of clinicobiologic correlations in 105 patients. Leuk Lymphoma. 2012;53:83–8.
22. Flanagan MB, Sathanoori M, Surti U, Soma L, Swerdlow SH. Cyogenetic abnormalities detected by fluorescence in situ hybridization on paraffin-embedded chronic lymphocytic leukemias/small lymphocytic lymphoma lymphoid tissue biopsy specimens. Am J Clin Pathol. 2008;130:620–7.
23. Amare PB, Gadage V, Jain H, et al. Clinicopathological impact of cytogenetic subgroups in B-cell chronic lymphocytic leukemia: experience from India. Indian J Cancer. 2013;50(3):261–7.
24. Clark HM, Jones DB, Wright DH. Cyogenetic and molecular studies of t(14;18) and t(14;19) in nodal and extranodal B-cell lymphoma. J Pathol. 1992;166:129–37.
25. Yabumoto K, Akasaka T, Muramatsu M, et al. Rearrangement of the 5′ cluster region of the bcl2 gene in lymphoid neoplasm: a summary of nine cases. Leukemia. 1996;10:970–7.
26. Damle JN, Waul T, Fais F, et al. IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840–7.
27. Ibrahim S, Keating M, Do KA, et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. *Blood*. 2001;98:181–6.
28. Del Poeta G, Maurillo L, Venditti A, et al. Clinical significance of CD38 expression in chronic lymphocytic leukemia. *Blood*. 2001;98:2633–9.
29. Fais F, Ghimetti F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. *J Clin Invest*. 1998;102:1515–5.
30. Hamblin TJ, Orchard JA, Gardiner A, Oscier DG, Davis Z, Stevenson FK. Immunoglobulin V genes and CD38 expression in CLL. *Blood*. 2000;95:2455–6.
31. Thunberg U, Johnson A, Roos G, et al. CD38 expression is a poor predictor for VH gene mutational status and prognosis in chronic lymphocytic leukemia. *Blood*. 2001;97:1892–4.
32. Damle RN, Wasil T, Allen SL, et al. Updated data on V gene mutation status and CD38 expression in CLL. *Blood*. 2000;95:2456–7.
33. Stilgenbauer S, Bullinger L, Lichter P, Döhner H, German CLL Study Group (GCLLSG). Chronic lymphocytic leukemia. Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. *Leukemia*. 2002;16(6):993–1007.
34. Kipps TJ. Immunoglobulin genes in chronic lymphocytic leukemia. *Blood Cells*. 1993;19(3):615–25.
35. Chiorazzi N, Ferrarini M. Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. *Blood*. 2011;117(6):781–91.
36. Küppers R, Klein U, Hansmann ML, Rajewsky K. Cellular origin of human B-cell lymphomas. *N Engl J Med*. 1999;341(20):1520–9.
37. Gaidano G, Foà R, Dalla-Favera R. Molecular pathogenesis of chronic lymphocytic leukemia. *J Clin Invest*. 2012;122(10):3432–8.
38. Seifert M, Sellmann L, Bloechdorn J, et al. Cellular origin and pathophysiology of chronic lymphocytic leukemia. *J Exp Med*. 2012;209(12):2183–98.